|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBOOKCENTRAL_ocn953657042 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
160716s2015 xx ob 001 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d CCO
|d OCLCO
|d COCUF
|d LOA
|d K6U
|d OCLCF
|d STF
|d PIFAG
|d FVL
|d MERUC
|d OCLCQ
|d ZCU
|d U3W
|d WRM
|d ICG
|d OCLCQ
|d VT2
|d OCLCQ
|d TKN
|d DKC
|d OCLCQ
|d UKAHL
|d OCLCQ
|d N$T
|d OCLCO
|
| 066 |
|
|
|c Zsym
|c (S
|
| 020 |
|
|
|a 1681081407
|
| 020 |
|
|
|a 9781681081403
|q (electronic bk.)
|
| 020 |
|
|
|z 9781681081410
|
| 035 |
|
|
|a (OCoLC)953657042
|
| 050 |
|
4 |
|a QR177
|b .C435 2015eb
|
| 082 |
0 |
4 |
|a 616.9041
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Manuela, Oliveira.
|
| 245 |
1 |
4 |
|a The challenges of antibiotic resistance in the development of new therapeutics.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2015.
|
| 300 |
|
|
|a 1 online resource (279 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Antimicrobial Agents ;
|v v. 1
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|6 880-01
|a FOREWORD ; PREFACE ; List of Contributors ; Introduction ; INTRODUCTION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Bacteriophages as Antibacterial Agents: Why are We Facing an Antibiotic Crisis and How Could Bacteriophages be of Help? ; 1. INTRODUCTION; 2. WHY ARE WE FACING AN ANTIBIOTIC (AB) CRISIS? ; 3. HOW TO RESOLVE THIS ANTIBIOTIC CRISIS? ; 4. BACTERIOPHAGES OR IN SHORT 'PHAGES'; 5. BACTERIOPHAGE THERAPY OR PHAGE THERAPY; 6. EXPERIMENTAL PHAGE THERAPY; 7. SAFETY ISSUES; 8. IN FACT WE LIVE IN AN "OCEAN" OF BACTERIOPHAGES; 9. SAFETY REQUIREMENTS FOR PHAGE THERAPY.
|
| 505 |
8 |
|
|a 10. THE POTENTIAL ADVANTAGES OF PHAGE THERAPY VERSUS ANTIBIOTICS11. PHAGE THERAPY IN PUBLIC HEALTH; 12. WHY PHAGE THERAPY IS NOT YET IMPLEMENTED?; CONCLUSIONS AND PERSPECTIVES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Antimicrobial Peptides ; INTRODUCTION; 1. WHAT ARE ANTIMICROBIAL PEPTIDES (AMPS); 1.1. Mode of Action; 1.2. Immune System; 1.3. Resistance; 2. CHRONOLOGY OF AMPS DISCOVERY -- A BRIEF HISTORY; 2.1. Classification of AMPs; 2.1.1. Biological Source; 2.1.2. Biological Functions; 2.1.3. Biosynthesis; 2.1.4. Molecular Properties; 2.1.5. Molecular Targets.
|
| 505 |
8 |
|
|a 2.1.6. Three-Dimensional (3D) Structure2.2. Currently Active AMPs Databases; 3. THERAPEUTIC APPLICATIONS OF AMPS; 3.1. Anticancer AMPs; 3.2. Antiviral AMPs; 3.3. Anti-parasitic AMPs; 3.4. New Generation of AMPs; CONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Probiotics: Ways of Action and Beneficial Effects ; 1. INTRODUCTION; 2. SELECTION OF PROBIOTICS; 3. COMMERCIALLY IMPORTANT PROBIOTICS; 4. MECHANISMS OF ACTION OF PROBIOTICS; 4.1. Immunomodulation; 4.2. Direct Effects on Other Microorganisms; 5. BENEFICIAL HEALTH EFFECTS OF PROBIOTICS.
|
| 505 |
8 |
|
|a 5.1. Alleviation of Lactose Intolerance5.2. Effect on Helicobacter Pylori Eradication ; 5.3. Anti-carcinogenic Effect; 5.4. Cholesterol-lowering Effects; 5.5. Allergy and Atopic Dermatitis; 5.6. Inflammatory Diseases and Bowel Syndromes ; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Immunotherapy ; 1. BACTERIAL INFECTIVITY, IMMUNE RESPONSE AND MULTIRESISTANT INFECTIONS : NEW PERSPECTIVES; 1.1. Introduction; 1.2. Host Resistance; 1.3. Bacterial Strategies for Evading, Surviving Host Defense Systems and Create Infection; 2. IMMUNOTHERAPY; 2.1. Introduction.
|
| 500 |
|
|
|a 2.10.2. Propionibacterium Acnes.
|
| 504 |
|
|
|a Includes bibliographical references at the end of each chapters and index.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Drug resistance in microorganisms.
|
| 650 |
|
7 |
|a Drug resistance in microorganisms
|2 fast
|
| 700 |
1 |
|
|a Serrano, Isa D.
|
| 776 |
0 |
8 |
|i Print version:
|a Manuela, Oliveira.
|t Challenges of antibiotic resistance in the development of new therapeutics.
|d Sharjah : Bentham Science Publishers, ©2015
|z 9781681081410
|
| 830 |
|
0 |
|a Frontiers in Antimicrobial Agents.
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=4412594
|z Texto completo
|
| 880 |
|
4 |
|6 264-00/Zsym
|c �[2015]
|
| 880 |
8 |
|
|6 505-01/(S
|a 2.2. Applications of Immunotherapy2.3. Passive Immunotherapy; 2.4. Passive Immunotherapy: Antibodies ; 2.5. Passive Immunotherapy: Adoptive T-cell Transfer; 2.6. Passive Immunotherapy: Immunomodulators; 2.7. Growth Factors; 2.7.1. Filgastrim ; 2.7.2. Sargramostim ; 2.7.3. Erythropoietin (EPO) ; 2.7.4. Insulin-like Growth Factor-1 (IGF-1); 2.8. Interleukins; 2.8.1. Interleukin 2; 2.8.2. Interleukin-8; 2.9. Interferons; 2.9.1. Human Interferon Alpha (HuIFN- α); 2.9.2. Recombinant-Feline Interferon Omega (rFeIFN- ω) ; 2.10. Nonspecific Immunostimulants; 2.10.1. Staphylococcal Protein A (SPA).
|
| 938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH32996503
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL4412594
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1108996
|
| 994 |
|
|
|a 92
|b IZTAP
|
